The deadline for abstract submission is June 1, 2017.
The 2017 Diagnostics Summit will address how Diagnostics are supporting prevention of hospital admissions across the UK. Drawing on best-practice and expertise from key leaders at the forefront of Diagnostics research and development , the Summit will explore how Diagnostics are being utilised at community and secondary health levels to prevent disease and infection.
We will explore:
Cell-free DNA-based screening and the potential for cell-based screening has upended the field of prenatal testing. While cell-free tests are being used more and more in the clinic, cell-based tests are still on the cusp of commercialization. With both types of tests still in need of improvements in order to truly replace invasive tests, the near-term challenge is determining where the field heads once both options are viable. This meeting will discuss updated comparisons and examine the implementation, insurance, and clinical challenges associated with each test.
Furthermore, with advances in DNA amplification and sequencing comes greater opportunity to garner more information. Much discussion needs to take place in regards to the role of preconception counseling, expanded carrier screening, whole genome versus whole exome sequencing, and the effect these and any prenatal testing may have on the decision to continue a pregnancy or perform fetal therapy.
Couples undergoing infertility treatments are more aware than ever of preimplantation genetic screening and diagnosis, yet patients and practitioners alike are still struggling with understanding the technologies being used, their capabilities and limitations, and their clinical, legal, and ethical implications. Cambridge Healthtech Institute’s Third Annual Reproductive Genetic Diagnostics conference aims to highlight a number of technologies and their differences, as well as how effective they are at uncovering a variety of genetic abnormalities. Considerations for mosaic embryos, biopsy techniques, and genetic counseling will also be discussed. Special attention will be paid to expanded carrier screening, its role in the direct-to-consumer market, and the potential for other molecular tests for infertility and implantation failure. Future directions for the role of gene editing and non-invasive embryo diagnostics will also be discussed.
With a focus on applications in healthcare, this conference is designed to help you discover how leaders in the field are using sequencing technology, the challenges they face and the solutions to overcome them.
Join us in examining the latest next-generation sequencing technologies, analysis methods and applications across topics at the frontier of genomics, including nanopore sequencing, personalised medicine and genetic screening.
To view the full list of topics and speakers, visit:
Oxford Global is proud to present the 13th Annual Biomarkers Congress to be held on 15-16 February 2018 in Manchester.
The congress covers novel developments in biomarker discovery and validation, translation into the clinic, personalised healthcare, Big data management, clinical diagnostics development. Key therapeutic focus areas include Immuno Oncology, Neuroscience, Respiratory, Metabolic and Cardiovascular Diseases.
Attended by over 300 biomarker experts, congress will include representatives from the companies including Bayer, Roche, Merck, UCB, Pfizer. The high quality and outstanding interactive programme includes 2 pre-event webinars, 50 expert presentations, a workshop and 8 round table discussions.
Do not miss out on the latest developments in biomarker innovations, state of the art technologies, and drivers into biomarker development such as precision medicine, immuno-assays and screening processes, histology, immunohistochemistry, big data analytics, new technologies in translation and the prediction of patient population.
View the Agenda here: http://bit.ly/2v4APod
Predictive and Efficacy Biomarkers in Cancer Research
Tuesday 28th November 2018 | 10am GMT
Hosted by Mattias Bergqvist, VP Clinical Development, Biovica International and Sue Burchill, Professor of Adolescent and Paediatric Cancer Research, Leeds Institute of Cancer and Pathology.
Register today for free: http://bit.ly/2xT7TR9
Can’t make the dates? Still register and a copy of the webinar recording will be sent to you.
For further information, prices & discounts please contact: email@example.com